Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.
about
Antituberculosis therapy for 2012 and beyondMycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosisNew anti-tuberculosis drugs and regimens: 2015 updatePipeline of drugs for related diseases: tuberculosisPlasma drug activity in patients on treatment for multidrug-resistant tuberculosisUnderstanding pharmacokinetics to improve tuberculosis treatment outcome.Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tubercuIn vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosisSusceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.Drug-resistant tuberculosis: emerging treatment options.Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood cultureWorld Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?siRNA Genome Screening Approaches to Therapeutic Drug Repositioning.Tuberculosis drugs: new candidates and how to find more.The oxazolidinones: past, present, and future.Is repositioning of drugs a viable alternative in the treatment of tuberculosis?The anti-tuberculosis agents under development and the challenges ahead.Synthetic investigational new drugs for the treatment of tuberculosis.Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants.Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis
P2860
Q26829101-3AB2CA03-774C-40C0-AF50-A254512B7832Q28537839-F54A6CE1-35BA-449D-80BF-2AB2DD3AEDDAQ28596775-CB8E105F-DA03-4CB0-B7A9-3A429B78F70BQ28818217-4C0D7833-911E-43E7-B325-DF519CFDE577Q30411475-5786F006-BD99-4236-B57B-E4E826B45234Q30411703-067369B2-1418-4121-BD47-D559DD2AED31Q30419537-355D56F2-F293-4394-A5D1-E430C289A5EDQ33427278-445F34DB-89B8-4B02-976C-699C8F89A0AEQ33760793-EA8793A5-81A8-4648-8842-4A23A41E2B2AQ33798120-23FE3B6D-E6B5-49E3-B3F7-6B3C9F9A2D6AQ33798173-A3CFD039-55BE-425B-9027-40BF0A6E7FD9Q34529109-C29D7560-8323-45CF-A2C7-B0EB99934D3CQ34737298-46BF594E-0274-49AE-8B58-F426210A86D9Q34922056-EFE22751-FA79-4ECF-90CC-43DAB6CD6094Q35683967-118B7D85-5C3B-43C0-8E66-0235C1E48A94Q36018542-AD084002-6647-44A3-9C56-3E8CDEBF0F28Q36094215-AAD4FCB0-D471-40D8-BC78-8D8921A4628CQ36893907-CAEE39F8-03D8-49D4-B558-9EB4F036A5CBQ36957270-FC12F0C2-530E-4DB0-A8F2-509A4DBD8A5BQ36969745-080AEBBD-EF2E-499C-B32E-F360B5793AF7Q37277365-BDEDA1A2-C649-4DEF-B6BC-B47C6C7C3F00Q37894691-3763D81F-335E-4EBB-BDC7-D55EDB12B7CDQ37970719-FAB33573-ED2A-40FC-A463-B4C51DCBA74EQ38053000-9D62D41B-46C3-4FFE-8901-29EE684A06D1Q38617197-6A5F23DF-606F-49EA-9CD7-B058310119ADQ38635790-93486A42-8DDE-4CDF-9BC5-3A007BB4E9EAQ38929509-A624FE67-8F58-43B2-A140-48C49870EEBFQ39321112-E86E6F34-D774-4358-B90F-83856B73A590Q40763975-F50693A6-8A84-4E50-86D5-134AE24EB8E5Q41789967-6FC89910-67BB-40AB-BA09-96B162FAAE4AQ48713291-4B7E79E9-2125-4E2D-9CC4-E1C98513F769Q53408541-6EB5FA84-E076-4ACB-BF25-87E9E169030EQ57775011-57E19479-A0FE-4F32-A185-874F8B90A382
P2860
Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacokinetics and whole-blo ...... -100480 in healthy volunteers.
@en
Pharmacokinetics and whole-blo ...... -100480 in healthy volunteers.
@nl
type
label
Pharmacokinetics and whole-blo ...... -100480 in healthy volunteers.
@en
Pharmacokinetics and whole-blo ...... -100480 in healthy volunteers.
@nl
prefLabel
Pharmacokinetics and whole-blo ...... -100480 in healthy volunteers.
@en
Pharmacokinetics and whole-blo ...... -100480 in healthy volunteers.
@nl
P2093
P356
P1476
Pharmacokinetics and whole-blo ...... U-100480 in healthy volunteers
@en
P2093
Annette M Silvia
Darcy Paige
Dessislava Dimitrova
Gerald Friedland
Lynn Ladutko
Paul F Miller
Robert S Wallis
Sheldon Campbell
Vikas Kumar
P304
P356
10.1086/655471
P407
P577
2010-09-01T00:00:00Z